Associated Papers
Genetic variation features of neonatal hyperbilirubinemia caused by inherited diseases.
You JY et al.
World Journal of Clinical Pediatrics, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM1_ESM.xlsx › Sheet1
SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.
Türkmen D et al.
International Journal of Molecular Sciences, 2024
Do Gene Polymorphisms Play a Role in Newborn Hyperbilirubinemia?
Hakan N et al.
Balkan Journal of Medical Genetics : Bjmg, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
35181665 (PubMed )
Supplement: 41525_2022_283_MOESM2_ESM.xlsx › Alleles
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.
Zhang L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
Identification of Genetic Risk Factors for Neonatal Hyperbilirubinemia in Fujian Province, Southeastern China: A Case-Control Study.
Zhou J et al.
Biomed Research International, 2018
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
Ramsey LB et al.
Genome Research, 2012
[Pharmacogenomics for adverse drug reactions].
Saito Y et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine, 2010
Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.
Saito A et al.
Journal of Human Genetics, 2009
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM et al.
Clinical Pharmacokinetics, 2006
Select a paper to view details